Details of the Drug Reposition

General Information of This Drug (ID: DMEXNZN)

Drug Name
GL-ONC1   DMEXNZN
Synonyms olvimulogene nanivacirepvec
Drug Type
Oncolytic virus therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Phase 1/2 [2]
Peritoneal carcinomatosis DISMNJQV 2D91 Phase 1/2 [3]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Peritoneal cavity cancer DISBT2JS 2C51.Z Phase 1 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02759588) GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)